Breakout Labs

Breakout Labs was founded by the Thiel Foundation in 211 and is based in San Francisco CA. Breakout Labs provides seed grants of $35 to 8-1 early stage companies per year. Companies must reach specific milestones in order to receive installments of the grant. Breakout Labs grants are in the form of a convertible note that if the company raises a Series A round will convert based on the Series A valuation, however if the company fails before raising a Series A round no debt will be due. Additionally when a portfolio company becomes revenue-generating or is acquired Breakout Labs receives a 3% royalty payment capped at 3x the value of the grant. Breakout Labs funds companies throughout the USA.
Lindy Fishburne
Executive Director 
Michelle Kim-Danely
Portfolio Manager 

BSI Capital Group

BSI Capital is a Single Family Office based in Mexico City Mexico. The firm is looking to make growth stage investments into healthcare companies generally in series C and D rounds or later. Due to the structure of the firm BSI has a highly variable investment size that will depend of the financial needs of the company. The firm is currently looking for new opportunities throughout the United States Mexico and Canada. The firm has no set number of investment in plans to make over the next 6-9 months.
Alejandra Paradones
CEO & Founder 

CDRD Ventures Canada

CDRD Ventures Inc. (CVI) is the commercialization vehicle of the Centre for Drug Research and Development (CDRD), Canada's national drug development and commercialization center that was founded in 2007 and is based in Vancouver, Canada. CVI seeks to advance promising drug development projects from CDRD using internal funds and through partnerships with international pharmaceutical companies, venture capital firms, biotech companies, and other funding agencies. CVI also seeks to in-license technologies from industry or non-CDRD affiliated research institutions. The firm considers both small molecule and biologic innovative technologies in virtually any therapeutic area.

Ms Natalie Dakers
President & CEO 
Mr Michael Lincoln
Chief Financial and Business Officer 

Chempetitive Group

Chempetitive Group is an integrated marketing communications agency focused exclusively on the life sciences. We work with biotech, medical device, pharmaceutical, chemical and tools/instrumentation companies of all sizes that around the globe. We develop winning strategies and campaigns that build brands and generate revenues. We love science. We understand science. And, we know how to effectively reach the scientific, clinical, medical and business communities that matter. 

Long live science. 

Visit us in San Diego, San Francisco, Chicago, Boston or Cambridge UK. 

Find out about us at http://www.chempetitive.com 

Erik Clausen
Erik Clausen
LinkedIn logo Managing Partner 
BIO

Erik Clausen is a managing partner at Chempetitive Group (http://www.chempetitive.com), a marketing communications firm that develops and implements strategies and drives results for life science and healthcare companies. Erik brings two decades of international experience helping life science, medical technology and healthcare organizations to reach and engage the right audiences.

Correlation Ventures United States

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.

Year Founded
2010
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
David Coats
Managing Director 

Diamond BioFund Taiwan

Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Winston Town
Vice President 
Haolin Sung
LinkedIn logo Director 

DreamCatcher Ventures United States

  

Tania Fernandez is the founder of Dream Catcher Ventures, an advisory firm founded to address the inefficiencies in the marketplace and to align the goals and aspirations of entrepreneurs with investors in the healthcare/biotech sector. It is focused on creating and building disruptive biotech/healthcare companies that are positioned to excel in global markets. The firm also has a strong focus on biotech companies that have assets/technologies that are relevant to the Indian market.

Dr. Fernandez is currently working with BioHealth Innovation on a $50M “Gap Fund” to invest in seed and early stage healthcare/biotech companies primarily in therapeutics, diagnostics, medtech and healthcare IT.

Tania has a doctorate in molecular oncology and a post doctorate in protein chemistry and genetic engineering. She has over fifteen years of experience in the life sciences and 10 years of venture capital investing experience in biotech/ life sciences/healthcare and healthcare delivery.

Tania Fernandez
Founder 

Excel Venture Management United States

Excel Venture Management is a venture capital firm that was founded in 2008 and is based in Boston, Massachusetts. The firm has managed one fund with committed capital of $125 million, and the firm is currently raising the second fund. Excel Venture Management seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $3 million to $ 5million. The firm plans to invest in 4-5 companies over the next 6-9 months and prefers to invest in companies based in US.

Year Founded
2008
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Eric Zimmerman
Kevin Liang

Golden Seeds

Golden Seeds is an investment group that was founded in 25 and is headquartered in New York with other offices in Boston Silicon Valley and Texas. The group currently invests out of the Golden Seeds angel network and the Golden Seeds venture funds. The group has managed 3 venture funds that are Golden Seeds Fund LP Golden Seeds Fund 2 LP and Innovate New York LP Fund. The Golden Seeds angel network has 32 members of which 1 are life science investors. Golden Seeds invests in companies with a female founder or CEO or with women in other C-level positions or with at least 1% of equity owned by women. Golden Seeds prefers to invest in companies with a valuation under $5 million, the group?s first-round equity investments generally range from $ .25 million to $2 million. The group invests in companies based across the US and Canada.
Bill Whitaker
Managing Director Co-Chair Life Science Section 

Green Park & Golf Ventures

Green Park & Golf Ventures (GPG) is a family office based in Dallas Texas. The firm was founded in 211 and is focused on healthcare companies. The firm makes seed venture and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $1K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.
Clay Heighten
Founding Partner 
JR Garcia
Principal 
Carl Soderstrom
Founding Partner